Dudediligence.

Monte Rosa Therapeutics, Inc

GLUENASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$9.2MSep ’24$60.6MDec ’24$84.9MMar ’25$23.2MJun ’25$12.8MSep ’25$2.8MDec ’25$4.2MMar ’26$9.0MJun ’26
Net income, by quarter
−$23.9MSep ’24$13.4MDec ’24$46.9MMar ’25−$12.3MJun ’25−$27.1MSep ’25−$46.1MDec ’25−$44.5MMar ’26−$43.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$0.00$75.6M$123.7M
Operating income−$72.9M−$112.4M−$143.3M−$81.1M−$54.2M
Net income−$74.0M−$108.5M−$135.4M−$72.7M−$38.6M
Operating cash flow−$59.4M−$92.5M−$43.8M$42.0M−$22.8M
Free cash flow−$69.1M−$105.4M−$62.8M$38.0M−$27.5M
Cash$346.1M$54.9M$128.1M$224.3M$129.9M
Shares outstanding46.5M49.3M50.1M61.5M65.5M